OVERVIEW

Community Practice Connections™ 14th Annual New York Lung Cancer Symposium® is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Activity Overview:
Community Practice Connections™: 14th Annual New York Lung Cancers Symposium consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Benefits of Participating:
• Learn about cutting-edge applications of immunotherapy in lung cancers.
• Discuss state-of-the-art approaches for patients with oncogene-driven non–small cell lung cancer (NSCLC).
• See how experts choose between the increasing therapeutic options in lung cancers.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Evaluate testing strategies to optimize tumor characterization and inform clinical decision making for the treatment of patients with lung cancers.
• Assess emerging clinical evidence regarding the treatment of patients with non-metastatic lung cancer.
• Describe clinical data concerning single-agent and combination immunotherapeutic approaches to manage lung cancers.
• Identify current and emerging therapeutic strategies over multiple lines of therapy for patients with oncogene-driven NSCLC subtypes.
• Evaluate strategies for patients without actionable oncogenic drivers, including the role of chemotherapies and antiangiogenic strategies.
• Discuss approaches to mitigate and manage treatment-related toxicities in the care of patients with lung cancers.